共 50 条
- [31] Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURAASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 69 - 70John, ThomasHerbst, RoyTsuboi, MasahiroGrohe, ChristianMajem, MargaritaGoldman, Jonathan W.Kim, Sang-WeMarmol, DominikaRukazenkov, YuriWu, Yi-Long
- [32] Clinical Effect of Adjuvant Chemotherapy on Stage IB NSCLC with High-Risk FactorsJOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S890 - S890Choi, J.Choi, S. I.Oh, J. Y.Lee, Y. S.Min, K. H.Hur, G. Y.Shim, J. J.Park, D. W.Park, C. K.Lee, S.
- [33] Results of molecular pathological Studies (NGS) in curatively operated Patients with Stage IB-IIIA NSCLCPNEUMOLOGIE, 2022, 76 : S79 - S79Kurz, S.Olive, E.Zaatar, M.Leschber, G.Grohe, C.
- [34] Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 studyANNALS OF ONCOLOGY, 2022, 33 : S71 - S71Felip, E.Altorki, N. K.Zhou, C.Vallieres, E.Vynnychenko, I. O.Akopov, A.Martinez-Marti, A.Chella, A.Bondarenko, I.Ursol, G.Levchenko, E.Kislov, N.Liersch, R.Belleli, R.McNally, V. A.Bennett, E.Gitlitz, B. J.Wakelee, H.
- [35] Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 studyONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 146 - 147Felip, EnriquetaAltorki, NasserZhou, CaicunVallieres, EricVynnychenko, IhorAkopov, AndreyMartinez-Marti, AlexChella, AntonioBondarenko, IgorUrsol, GrygoriiLevchenko, EvgenyKislov, NikolayLiersch, RuedigerBelleli, RossellaMcnally, VirginiaBennett, ElizabethGitlitz, BarbaraWakelee, Heather
- [36] A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Wakelee, Heather A.Altorki, Nasser K.Vallieres, EricZhou, CaicunZuo, YunxiaHowland, MichaelXia, FanSandler, AlanFelip, Enriqueta
- [37] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)Herbst, Roy S.Tsuboi, MasahiroJohn, TomKato, TerufumiMajem, MargaritaGrohe, ChristianWang, JieGoldman, Jonathan W.Lu, ShunSu, Wu-ChouDe Marinis, FilippoShepherd, Frances A.Lee, Ki HyeongLe, NhieuDechaphunkul, AruneeKowalski, Dariusz M.Poole, LynneStachowiak, MartaRukazenkov, YuriWu, Yi-Long
- [38] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)Herbst, Roy S.Tsuboi, MasahiroJohn, TomKato, TerufumiMajem, MargaritaGrohe, ChristianWang, JieGoldman, Jonathan W.Lu, ShunSu, Wu-Choude Marinis, FilippoShepherd, Frances A.Lee, Ki HyeongLe, NhieuDechaphunkul, AruneeKowalski, Dariusz M.Poole, LynneStachowiak, MartaRukazenkov, YuriWu, Yi-Long
- [39] IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wakelee, Heather A.Altorki, Nasser K.Zhou, CaicunCsoszi, TiborVynnychenko, Ihor O.Goloborodko, OleksandrLuft, AlexanderAkopov, AndreyMartinez-Marti, AlexKenmotsu, HirotsuguChen, Yuh-MinChella, AntonioSugawara, ShunichiGitlitz, Barbara J.Bennett, ElizabethWu, FanYi, JingDeng, YuMcCleland, MarkFelip, Enriqueta
- [40] LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLCJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S975 - S976Goldman, J.Besse, B.Wu, Y.Yang, J. C.Paz-Ares, L.Drilon, A.Johnson, M.Xia, M.Chao, B. H.Tsuboi, M.